Bendroflumethiazide

Summary

Bendroflumethiazide (CHEMBL1684) is an approved small-molecule diuretic (ATC C03AA01); indicated across 2 conditions including cardiovascular disorder and hypertensive disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: C03AA01
• Indications: 2 conditions
• Clinical trials: 4
• Chemistry: 421.4 Da · C15H14F3N3O4S2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1684
Name	Bendroflumethiazide
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	2315
ChEBI	CHEBI:3013
ATC	C03AA01
Molecular formula	C15H14F3N3O4S2
Molecular weight	421.4
InChIKey	HDWIHXWEUNVBIY-UHFFFAOYSA-N

SMILES: C1=CC=C(C=C1)CC2NC3=C(C=C(C(=C3)C(F)(F)F)S(=O)(=O)N)S(=O)(=O)N2

IUPAC name: 3-benzyl-1,1-dioxo-6-(trifluoromethyl)-3,4-dihydro-2H-1lambda6,2,4-benzothiadiazine-7-sulfonamide

ChEBI definition: A sulfonamide consisting of 7-sulfamoyl-3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide in which the hydrogen at position 6 is substituted by a trifluoromethyl group and that at position 3 is substituted by a benzyl group.

Pharmacological roles (ChEBI): diuretic, antihypertensive agent.

Also known as: Aprinox, Bendroflumethiazide, Bendroflumethiazide component of corzide, Bendroflumetiazida, Berkozide, Centyl, Naturetin, Naturetin-10, Naturetin-2.5, Naturetin-5, Neo-bendromax 2.5, Neo-bendromax 5

Patent coverage: 3,990 distinct patent families (14,097 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 7 (assay-derived). Sample: Lysine-specific demethylase 4E, Prelamin-A/C, Carbonic anhydrase 2, Sodium-dependent dopamine transporter, Cytochrome P450 3A4, Aldehyde dehydrogenase 1A1, Bile salt export pump.

Bioactivity

ChEMBL activities: 3 potent at pChembl ≥ 5 of 9 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
LMNA	6.3	Potency	501.2	nM	CHEMBL_ACT_3639227
CA2	5.77	Kd	1700	nM	CHEMBL_ACT_26047527
SLC6A3	5.5	AC50	3200	nM	CHEMBL_ACT_25124051

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
cardiovascular disorder	4	MONDO:0004995	EFO:0000319
hypertensive disorder	4	MONDO:0005044	EFO:0000537

Clinical trials

Total trials: 4.

Phase distribution

Phase	Trials
PHASE1	3
PHASE4	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02235402	PHASE4	COMPLETED	A Randomised, Parallel-group, Double-blind, Double-dummy Study to Compare the Effects of Lacidipine Versus Bendrofluazide on Markers of Platelet Activation and Haemorheological Factors in Hypertensive Patients
NCT05753059	PHASE1	RECRUITING	Mechanisms of Diuretic Resistance in Heart Failure, Aim 2
NCT00647660	PHASE1	COMPLETED	Fasting Study of Nadolol/Bendroflumethiazide Tablets 80 mg/5 mg and Corzide® Tablets 80 mg/5 mg
NCT00648297	PHASE1	COMPLETED	Fed Study of Nadolol/Bendroflumethiazide Tablets 80 mg/5 mg and Corzide® Tablets 80 mg/5 mg

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).